Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02302196
Other study ID # KPNW Fat Grafting 001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2015
Est. completion date July 13, 2021

Study information

Verified date August 2021
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of breast reconstruction using Autologous Fat Grafting (AFG) for women post lumpectomy that have contour defects. The study hypothesis is that AFG has emerged as a less invasive alternative to breast reconstruction post mastectomy. AFG could be used to treat breast contour defects with much less invasive outpatient surgery, using the patient's own cells and tissues, which overall reduces risk.


Description:

About 200 women at Kaiser Permanente Northwest will be in this study. The study will include about 100 women who have had a lumpectomy and consent to be in the research arm and have AFG and 100 from the control arm (retrospective chart review). Autologous Fat Grafting Arm: Breast-Q survey of patient satisfaction will be collected before and after AFG. Assessments will be done 3 months post grafting for efficacy (excellent 100% correction of defect), good (75% correction of defect), fair (50% correction of defect), poor 25% or less correction of defect) result will be recorded. AFG may be repeated x 2 at a 3-6 month interval if deemed necessary by the treating surgeon, then reassessed again 3 months later in the same way. A mammographic assessment of the breast, scored by radiologist in a 6 step scoring system (BIRADS score) will be done 1 year after AFG. BIRADS scores and new physical finding will continue to be collected for a 5 year period post AFG post lumpectomy group. Control (non-Autologous Fat Grafting) arm: Retrospective chart review for women who have undergone standard treatment to treatment to reconstruct their breasts. Data collected will include; BIRADS scores as well as frequency of subsequent surgical intervention (as necessitated by increased BIRADS scores or by new physical findings on exam) over a 5 year period post lumpectomy. .


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date July 13, 2021
Est. primary completion date July 13, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women - Age 18 > y/o - If patient has had lumpectomy and radiation, need to be at least 3 years out from completion of radiation - Must be a Kaiser Permanente Northwest Member Exclusion Criteria: - Active smokers, cannot quit smoking for at least one month before and after procedures - Patients who have such extensive skin scarring that elasticity is lost - Patients who have little to no subcutaneous donor fat - Patients with BIRAD's 3 or greater mammograms after treatment - Patients with aggressive cancer for which cure is the goal (do not want to exclude patients that want palliative procedure) - inflammatory breast cancer - Patients with triple negative cancer - ER -, PR -, Her2-neu - - Patients with BRCA or CHEK-2 gene mutations or those with strong family history of breast cancer [more than 2 first degree relatives with breast cancer] - Patients that have had a lumpectomy for breast cancer who have declined radiation therapy when it was recommended to reduce risk of local recurrence (should not exclude patients over 70 y/o who have elected to have lumpectomy and anti-estrogen therapy instead of lumpectomy and radiation) - Oncoplastic reduction patients - Comorbidities that preclude multiple procedures being done - Pregnant women

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Autologous Fat Grafting of the Breast
In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
Other:
Control Arm
Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.

Locations

Country Name City State
United States Kaiser Permanente NW Region, Sunnybrook Medical Office Building Clackamas Oregon

Sponsors (1)

Lead Sponsor Collaborator
Kaiser Permanente

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of Autologous Fat Grafting (AFG) compared to standard breast reconstruction for lumpectomy, as measured by the BIRADS scores The experimental AFG group will have the same or less change in the BIRADS scores than the control non-AFG group. 5 years for lumpectomy
Secondary Women undergoing Autologous Fat (AFG) Grafting of the breast The Breast Q survey will be administered to women before and after the AFG procedure Prior to AFG and 1 year after procedure
See also
  Status Clinical Trial Phase
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Completed NCT01271738 - Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer N/A
Completed NCT00217815 - Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer Phase 1/Phase 2
Terminated NCT00128362 - Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer Phase 2
Completed NCT00571987 - Pilot Study of Radiofrequency Ablation of Breast Cancer Lumpectomy Sites to Decrease Re-operation Phase 1/Phase 2
Terminated NCT02669914 - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors Phase 2
Completed NCT00530868 - Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer Phase 2
Completed NCT02658708 - Bright Light on Fatigue in Women Being Treated for Breast Cancer Phase 1
Completed NCT02891681 - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment N/A
Terminated NCT01498588 - Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer Phase 2
Completed NCT00573495 - Multipeptide Vaccine for Advanced Breast Cancer Phase 1
Completed NCT02595372 - Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy Phase 2
Terminated NCT02913729 - Pre- Versus Postoperative Accelerated Partial Breast Irradiation N/A
Recruiting NCT05837455 - NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer Phase 2
Active, not recruiting NCT00572481 - Axillary Reverse Mapping Phase 2
Active, not recruiting NCT05716542 - Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial) N/A
Recruiting NCT04968964 - Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing N/A
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01118624 - Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer Phase 2